NASDAQ:BEAM Beam Therapeutics (BEAM) Stock Forecast, Price & News $33.45 -0.91 (-2.65%) (As of 06/8/2023 ET) Add Compare Share Share Today's Range$32.81▼$34.6650-Day Range$29.32▼$35.9952-Week Range$28.04▼$73.27Volume491,356 shsAverage Volume888,383 shsMarket Capitalization$2.55 billionP/E RatioN/ADividend YieldN/APrice Target$67.91 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Beam Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.70 Rating ScoreUpside/Downside103.0% Upside$67.91 Price TargetShort InterestBearish21.04% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.33Based on 5 Articles This WeekInsider TradingSelling Shares$288,945 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($5.50) to ($6.00) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.66 out of 5 starsMedical Sector816th out of 986 stocksBiological Products, Except Diagnostic Industry130th out of 160 stocks 3.4 Analyst's Opinion Consensus RatingBeam Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.70, and is based on 7 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $67.91, Beam Therapeutics has a forecasted upside of 103.0% from its current price of $33.45.Amount of Analyst CoverageBeam Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted21.04% of the float of Beam Therapeutics has been sold short.Short Interest Ratio / Days to CoverBeam Therapeutics has a short interest ratio ("days to cover") of 13.4, which indicates bearish sentiment.Change versus previous monthShort interest in Beam Therapeutics has recently increased by 3.30%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldBeam Therapeutics does not currently pay a dividend.Dividend GrowthBeam Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BEAM. Previous Next 2.4 News and Social Media Coverage News SentimentBeam Therapeutics has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Beam Therapeutics this week, compared to 5 articles on an average week.Search Interest8 people have searched for BEAM on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows7 people have added Beam Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Beam Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $288,945.00 in company stock.Percentage Held by InsidersOnly 4.40% of the stock of Beam Therapeutics is held by insiders.Percentage Held by Institutions76.70% of the stock of Beam Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Beam Therapeutics are expected to decrease in the coming year, from ($5.50) to ($6.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Beam Therapeutics is -7.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Beam Therapeutics is -7.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBeam Therapeutics has a P/B Ratio of 3.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Beam Therapeutics (NASDAQ:BEAM) StockBeam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.Read More Receive BEAM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Beam Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BEAM Stock News HeadlinesJune 8, 2023 | msn.comWomen's gymnastics has highest concussion risk among college sports in preseasonJune 6, 2023 | msn.comSonos Beam soundbar just got an unprecedented price cutJune 9, 2023 | Vantage Point (Ad)Instantly Find Hidden Trade OpportunitiesThere’s a tool that scans and picks the best stocks…how you approach the trades is up to you. But when you’re forecasting 1 – 3 days in advance, it’s not really a guessing game. Stop guessing and start predicting to add consistency to your trades… no matter what happens in the market. June 3, 2023 | news.yahoo.comJim Beam Just Dropped a New 17-Year-Old Bourbon Meant to Highlight “Kentucky Terroir”June 2, 2023 | americanbankingnews.comAnalysts Set Beam Therapeutics Inc. (NASDAQ:BEAM) Target Price at $67.91May 30, 2023 | finance.yahoo.comGlobal Radiation Therapy Market Report 2023: Featuring Ion Beam Applications, Siemens Healthineers, Accuray, Elekta, ViewRay & HitachiMay 30, 2023 | finance.yahoo.comGlobal Radiation Therapy Market Report 2023: Surface-Guided Radiotherapy Boosts SectorMay 30, 2023 | finance.yahoo.comGT Medical Technologies Marks a Clinical Milestone: 200th Patient Enrolled in the Multicenter Observational Registry of GammaTile® TherapyJune 9, 2023 | Behind the Markets (Ad)U.S. Loses to China in Shocking WAR GAMES=== BREAKING === U.S. Loses to China in Shocking WAR GAMES Pentagon says new "living missile" key to winning a future conflict. Investors stand to reap 35,960% on shares of the small defense contractor that makes powerful new weapon. Get the name of the stock here >>>May 29, 2023 | msn.comPioneering proton beam therapy treated my breast cancerMay 27, 2023 | msn.comYakuza Kiwami 2: Unlock Beam’s Secret Weapon Shop (Beam's Backroom Cache Substory)May 25, 2023 | markets.businessinsider.comGenome Medical Supporting Beam Therapeutics on its Sickle Cell Disease Clinical TrialMay 20, 2023 | seekingalpha.comBeam Therapeutics: Base Editing Leader With Major Catalyst Next YearMay 18, 2023 | msn.comProton therapy, touted as cancer killer without side effects, set for Israel debutMay 17, 2023 | americanbankingnews.comBeam Therapeutics Inc. (NASDAQ:BEAM) Forecasted to Earn Q2 2023 Earnings of ($1.18) Per ShareMay 16, 2023 | yahoo.comThe Distillery Behind Jim Beam Is Releasing Its First American Single Malt WhiskeyMay 16, 2023 | msn.comTata Memorial now 1st govt facility in India to offer breakthrough ‘proton therapy’ for cancerMay 16, 2023 | finance.yahoo.comCathie Wood Is Loading Up on These 3 Stocks Down 70% or More. Should You?May 16, 2023 | americanbankingnews.comBrokers Issue Forecasts for Beam Therapeutics Inc.'s Q2 2023 Earnings (NASDAQ:BEAM)May 16, 2023 | americanbankingnews.comBeam Therapeutics Inc. (NASDAQ:BEAM) Forecasted to Post Q2 2023 Earnings of ($1.15) Per ShareMay 15, 2023 | marketwatch.comProton Beam Therapy Equipment Market New Insight Report | 2023-2031May 14, 2023 | americanbankingnews.comBarclays Trims Beam Therapeutics (NASDAQ:BEAM) Target Price to $41.00May 12, 2023 | msn.comBarclays Maintains Beam Therapeutics (BEAM) Equal-Weight RecommendationMay 12, 2023 | msn.comCitigroup Maintains Beam Therapeutics (BEAM) Buy RecommendationMay 12, 2023 | msn.comCitigroup Maintains Beam Therapeutics (BEAM) Buy RecommendationMay 12, 2023 | americanbankingnews.comBeam Therapeutics (NASDAQ:BEAM) PT Lowered to $42.00May 11, 2023 | marketwatch.com8-K: Beam Therapeutics Inc.See More Headlines BEAM Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BEAM Company Calendar Last Earnings5/10/2023Today6/08/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BEAM CUSIPN/A CIK1745999 Webwww.beamtx.com Phone857-327-8775FaxN/AEmployees341Year Founded2017Price Target and Rating Average Stock Price Forecast$67.91 High Stock Price Forecast$105.00 Low Stock Price Forecast$37.00 Forecasted Upside/Downside+103.0%Consensus RatingModerate Buy Rating Score (0-4)2.70 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($4.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-289,090,000.00 Net Margins-412.45% Pretax Margin-374.76% Return on Equity-42.04% Return on Assets-23.25% Debt Debt-to-Equity RatioN/A Current Ratio4.92 Quick Ratio4.92 Sales & Book Value Annual Sales$60.92 million Price / Sales41.85 Cash FlowN/A Price / Cash FlowN/A Book Value$10.41 per share Price / Book3.21Miscellaneous Outstanding Shares76,220,000Free Float72,863,000Market Cap$2.55 billion OptionableNot Optionable Beta1.63 Social Links Key ExecutivesMr. John M. Evans M.B.A. (Age 45)CEO & Director Comp: $1.02MDr. Giuseppe Ciaramella Ph.D. (Age 54)Pres & Chief Scientific Officer Comp: $890.79kMs. Terry-Ann Burrell M.B.A. (Age 46)CFO & Treasurer Comp: $687.52kDr. Feng Zhang Ph.D.Co-FounderDr. David R. Liu Ph.D.Co-FounderDr. J. Keith Joung M.D.Ph.D., Co-FounderDr. Nicole Gaudelli Ph.D.Co-FounderDr. Alexis Komor Ph.D.Co-FounderMs. Suzanne Fleming (Age 62)Chief Accounting Officer Mr. Brian Riley (Age 46)Sr. VP of Technical Operations More ExecutivesKey CompetitorsImmunovantNASDAQ:IMVTImmunocoreNASDAQ:IMCRRevolution MedicinesNASDAQ:RVMDKrystal BiotechNASDAQ:KRYSArcellxNASDAQ:ACLXView All CompetitorsInsiders & InstitutionsProShare Advisors LLCSold 1,961 shares on 5/26/2023Ownership: 0.017%Capital Impact Advisors LLCBought 445 shares on 5/23/2023Ownership: 0.017%University of Texas Texas AM Investment Managment Co.Bought 59,839 shares on 5/22/2023Ownership: 0.079%JPMorgan Chase & Co.Sold 19,280 shares on 5/18/2023Ownership: 0.947%New York State Common Retirement FundSold 10,315 shares on 5/18/2023Ownership: 0.059%View All Insider TransactionsView All Institutional Transactions BEAM Stock - Frequently Asked Questions Should I buy or sell Beam Therapeutics stock right now? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beam Therapeutics in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BEAM shares. View BEAM analyst ratings or view top-rated stocks. What is Beam Therapeutics' stock price forecast for 2023? 10 Wall Street research analysts have issued 12-month target prices for Beam Therapeutics' shares. Their BEAM share price forecasts range from $37.00 to $105.00. On average, they predict the company's share price to reach $67.91 in the next twelve months. This suggests a possible upside of 103.0% from the stock's current price. View analysts price targets for BEAM or view top-rated stocks among Wall Street analysts. How have BEAM shares performed in 2023? Beam Therapeutics' stock was trading at $39.11 on January 1st, 2023. Since then, BEAM stock has decreased by 14.5% and is now trading at $33.45. View the best growth stocks for 2023 here. When is Beam Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our BEAM earnings forecast. How were Beam Therapeutics' earnings last quarter? Beam Therapeutics Inc. (NASDAQ:BEAM) released its earnings results on Wednesday, May, 10th. The company reported ($1.33) EPS for the quarter, topping the consensus estimate of ($1.36) by $0.03. The company had revenue of $24.21 million for the quarter, compared to analyst estimates of $14.41 million. Beam Therapeutics had a negative trailing twelve-month return on equity of 42.04% and a negative net margin of 412.45%. What ETFs hold Beam Therapeutics' stock? ETFs with the largest weight of Beam Therapeutics (NASDAQ:BEAM) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), ARK Genomic Revolution ETF (ARKG), iShares Genomics Immunology and Healthcare ETF (IDNA), ARK Innovation ETF (ARKK), Global X Genomics & Biotechnology ETF (GNOM), Horizon Kinetics Medical ETF (MEDX), Jacob Forward ETF (JFWD) and SPDR S&P Biotech ETF (XBI). What other stocks do shareholders of Beam Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Beam Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Editas Medicine (EDIT), Cisco Systems (CSCO), Block (SQ), Skyworks Solutions (SWKS), Akoustis Technologies (AKTS), Invitae (NVTA), QUALCOMM (QCOM) and Alector (ALEC). When did Beam Therapeutics IPO? (BEAM) raised $101 million in an IPO on Thursday, February 6th 2020. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and Barclays acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. What is Beam Therapeutics' stock symbol? Beam Therapeutics trades on the NASDAQ under the ticker symbol "BEAM." Who are Beam Therapeutics' major shareholders? Beam Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (11.84%), FMR LLC (8.15%), BlackRock Inc. (7.08%), Temasek Holdings Private Ltd (5.48%), Farallon Capital Management LLC (4.60%) and State Street Corp (4.25%). Insiders that own company stock include Fmr Llc, Giuseppe Ciaramella, Graham K Cooper, John M Evans, John M Evans and Terry-Ann Burrell. View institutional ownership trends. How do I buy shares of Beam Therapeutics? Shares of BEAM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Beam Therapeutics' stock price today? One share of BEAM stock can currently be purchased for approximately $33.45. How much money does Beam Therapeutics make? Beam Therapeutics (NASDAQ:BEAM) has a market capitalization of $2.55 billion and generates $60.92 million in revenue each year. The company earns $-289,090,000.00 in net income (profit) each year or ($4.45) on an earnings per share basis. How many employees does Beam Therapeutics have? The company employs 341 workers across the globe. Does Beam Therapeutics have any subsidiaries? The following companies are subsidiares of Beam Therapeutics: Blink Therapeutics Inc..Read More How can I contact Beam Therapeutics? Beam Therapeutics' mailing address is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. The official website for the company is www.beamtx.com. The company can be reached via phone at 857-327-8775 or via email at investors@beamtx.com. This page (NASDAQ:BEAM) was last updated on 6/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beam Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.